Check out which companies are making headlines before the bell:

Merck – The drugmaker earned an adjusted $1.11 per share for the third quarter, beating estimates by eight cents a share. Revenue did fall short of forecast, however. Merck reported a nearly tripling of sales for its cancer drug Keytruda, but also said a cyberattack during the quarter impacted its overall revenue.